Scott Ullem - Edwards Lifesciences Chief Financial Officer, Corporate Vice President
| EW Stock | USD 86.45 0.79 0.91% |
President
Mr. Scott B. Ullem is Chief Financial Officer, Corporationrationrate Vice President of the Edwards Lifesciences Corporationrationrtion. Mr. Ullem became Corporationrationrate Vice President, Chief Financial Officer in January 2014. Prior to joining Edwards, he served from May 2010 to December 2013 as Chief Financial Officer of Bemis Company Inc., a Fortune 500 publicly traded global supplier of packaging and pressure sensitive materials used in leading food, consumer, and healthcare products since 2014.
| Age | 57 |
| Tenure | 10 years |
| Address | One Edwards Way, Irvine, CA, United States, 92614 |
| Phone | 949 250 2500 |
| Web | https://www.edwards.com |
Scott Ullem Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Ullem against Edwards Lifesciences stock is an integral part of due diligence when investing in Edwards Lifesciences. Scott Ullem insider activity provides valuable insight into whether Edwards Lifesciences is net buyers or sellers over its current business cycle. Note, Edwards Lifesciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Edwards Lifesciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Ullem over three months ago Exercise or conversion by Scott Ullem of 1970 shares of Berry Global subject to Rule 16b-3 | ||
Scott Ullem over a year ago Acquisition by Scott Ullem of 9000 shares of Berry Global subject to Rule 16b-3 |
Edwards Lifesciences Management Efficiency
The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.07 in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Michael Harrington | Waters | 59 | |
| Nicholas Naclerio | Illumina | 53 | |
| Susan Hardy | Charles River Laboratories | N/A | |
| William Barbo | Charles River Laboratories | 63 | |
| Gregory Herrema | Thermo Fisher Scientific | 52 | |
| Francis Kim | Waters | 51 | |
| Jonathan Seaton | Illumina | N/A | |
| Alicia Rodriguez | Agilent Technologies | N/A | |
| Michael Knell | Charles River Laboratories | 47 | |
| Robert Carson | Waters | 46 | |
| Robert McMahon | Agilent Technologies | 55 | |
| David Johst | Charles River Laboratories | 57 | |
| Peter Hornstra | Thermo Fisher Scientific | 59 | |
| Mark Stevenson | Thermo Fisher Scientific | 57 | |
| Nancy Gillett | Charles River Laboratories | 58 | |
| Michael Boxer | Thermo Fisher Scientific | 58 | |
| Patrick Durbin | Thermo Fisher Scientific | 51 | |
| Sam Samad | Illumina | 48 | |
| Dominique Grau | Agilent Technologies | 65 | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
| Paul Bianchi | Illumina | 53 | |
Management Performance
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.12 |
Edwards Lifesciences Corp Leadership Team
Elected by the shareholders, the Edwards Lifesciences' board of directors comprises two types of representatives: Edwards Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edwards. The board's role is to monitor Edwards Lifesciences' management team and ensure that shareholders' interests are well served. Edwards Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edwards Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul LaViolette, Independent Director | ||
| John Cardis, Independent Director | ||
| Wesley Schack, Presiding Independent Director | ||
| Larry Wood, Corporate Vice President - Transcatheter Aortic Valve Replacement | ||
| Leslie Heisz, Independent Director | ||
| Catherine Szyman, Corporate Vice President - Critical Care | ||
| Arnold Pinkston, Corporate Counsel | ||
| Barbara McNeil, Independent Director | ||
| Steven Loranger, Independent Director | ||
| Scott Ullem, Chief Financial Officer, Corporate Vice President | ||
| Patrick Verguet, Corporate VP of EMEA, Canada and Latin America | ||
| Kieran Gallahue, Independent Director | ||
| Nicholas Valeriani, Independent Director | ||
| Heisz Stone, Independent Director | ||
| Mark Wilterding, Vice Relations | ||
| MD FACC, Corporate Officer | ||
| Angela Fuente, Director Engineering | ||
| Martha Marsh, Lead Independent Director | ||
| Daveen Chopra, Corporate Vice President - Surgical Structural Heart | ||
| Huimin Wang, Corporate Vice President - Japan, Asia and Pacific | ||
| JeanLuc Lemercier, Corporate Vice President - EMEA (Europe, Middle East and Africa) | ||
| Christine McCauley, Corporate Resources | ||
| William Link, Independent Director | ||
| Gary Sorsher, Senior Compliance | ||
| Ramona Sequeira, Independent Director | ||
| Bernard Zovighian, Corporate Vice President -Surgical Heart Valve Therapy | ||
| David Erickson, Vice President - Investor Relations | ||
| Daniel Lippis, Greater Japan | ||
| Donald Bobo, Corporate Vice President - Strategy and Corporate Development | ||
| Todd Brinton, Co Officer | ||
| Dirksen Lehman, Corporate Affairs | ||
| Finn Haley, Vice Development | ||
| Michael Mussallem, Chairman of the Board, Chief Executive Officer |
Edwards Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edwards Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.39 % | ||||
| Current Valuation | 51.1 B | ||||
| Shares Outstanding | 601.93 M | ||||
| Shares Owned By Insiders | 0.88 % | ||||
| Shares Owned By Institutions | 84.00 % | ||||
| Number Of Shares Shorted | 10.38 M | ||||
| Price To Earning | 32.77 X |
Pair Trading with Edwards Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edwards Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edwards Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Edwards Stock
| 0.81 | ELMD | Electromed | PairCorr |
| 0.76 | FEMY | Femasys Financial Report 9th of May 2024 | PairCorr |
Moving against Edwards Stock
| 0.89 | IVP | Inspire Veterinary | PairCorr |
| 0.73 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
| 0.65 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
| 0.51 | DYNT | Dynatronics Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 2.3 | Revenue Per Share 9.897 | Quarterly Revenue Growth 0.138 | Return On Assets 0.1225 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.